Publications
Detailed Information
Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Paick, Jae-Seung | - |
dc.contributor.author | Kim, Je Jong | - |
dc.contributor.author | Kim, Sae Chul | - |
dc.contributor.author | Moon, Ki Hak | - |
dc.contributor.author | Park, Kwangsung | - |
dc.contributor.author | Yang, Dae Yul | - |
dc.contributor.author | Suh, Jun-Kyu | - |
dc.contributor.author | Min, Kweon Sik | - |
dc.date.accessioned | 2012-06-14T06:29:04Z | - |
dc.date.available | 2012-06-14T06:29:04Z | - |
dc.date.issued | 2010-09 | - |
dc.identifier.citation | JOURNAL OF SEXUAL MEDICINE; Vol.7 9; 3143-3152 | ko_KR |
dc.identifier.issn | 1743-6095 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77073 | - |
dc.description.abstract | Introduction. Mirodenafil is a recently developed oral phosphodiesterase type 5 inhibitor, which was observed to significantly improve erectile function and was well tolerated in men with broad-spectrum erectile dysfunction (ED). Aim. To investigate the efficacy and safety of mirodenafil treatment compared with placebo in men taking at least one antihypertensive medication. Methods. A multicenter, double-blind, placebo-controlled, parallel group, fixed-dose study was conducted with 109 subjects who were randomized to placebo or mirodenafil 100 mg for 12 weeks on an "as needed" basis. Main Outcome Measures. The primary efficacy measures were the changes from baseline in sum of scores on International Index of Erectile Function-erectile function domain (IIEF-EF) questions 1 to 5 and 15 with treatment. The secondary efficacy measures included scores on IIEF question 3 and 4 (Q3 and Q4), all domain scores of IIEF, and Sexual Encounter Profile Question 2 and 3 (SEP2 and SEP3) along with responses to Global Assessment Question (GAQ) and Life Satisfaction Checklist (LSC). The safety assessments included laboratory tests, vital signs, 12-lead electrocardiogram recordings, and patients` reporting of adverse events. Results. The mirodenafil group showed significantly greater increase in IIEF-EF scores at 12 weeks compared with the placebo group (9.35 +/- 6.86 vs. 2.66 +/- 6.44, P < 0.001). The mirodenafil group also demonstrated significantly greater improvement in scores of IIEF Q3 and Q4, other four domains of IIEF, SEP2, SEP3, and LSC along with percentages of patients responding positively to GAQ compared with the placebo group. During the study, no clinically significant changes were observed regarding blood pressure, heart rate, electrocardiographic findings, or laboratory values. Facial flushing and headache were the most common treatment-associated adverse events, which were mild or moderate in severity, resolving spontaneously. Conclusions. Mirodenafil was effective and safe in men with ED concomitantly taking antihypertensive medications. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | Erectile Dysfunction | ko_KR |
dc.subject | PDE5 inhibitor | ko_KR |
dc.subject | Antihypertensives | ko_KR |
dc.subject | Mirodenafil | ko_KR |
dc.title | Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 백재승 | - |
dc.contributor.AlternativeAuthor | 김재종 | - |
dc.contributor.AlternativeAuthor | 김새철 | - |
dc.contributor.AlternativeAuthor | 문기학 | - |
dc.contributor.AlternativeAuthor | 민권식 | - |
dc.contributor.AlternativeAuthor | 박광성 | - |
dc.contributor.AlternativeAuthor | 서준규 | - |
dc.contributor.AlternativeAuthor | 양대열 | - |
dc.identifier.doi | 10.1111/j.1743-6109.2010.01926.x | - |
dc.citation.journaltitle | JOURNAL OF SEXUAL MEDICINE | - |
dc.description.citedreference | Paick JS, 2009, J SEX MED, V6, P3166, DOI 10.1111/j.1743-6109.2009.01456.x | - |
dc.description.citedreference | Araujo AB, 2009, J SEX MED, V6, P2445, DOI 10.1111/j.1743-6109.2009.01354.x | - |
dc.description.citedreference | Kim BH, 2009, CLIN THER, V31, P1234, DOI 10.1016/j.clinthera.2009.06.008 | - |
dc.description.citedreference | Paick JS, 2008, J SEX MED, V5, P2672, DOI 10.1111/j.1743-6109.2008.00945.x | - |
dc.description.citedreference | Park HJ, 2008, J SEX MED, V5, P2405, DOI 10.1111/j.1743-6109.2008.00864.x | - |
dc.description.citedreference | Lee J, 2007, RAPID COMMUN MASS SP, V21, P1139, DOI 10.1002/rcm.2943 | - |
dc.description.citedreference | Shin HI, 2006, J LABELLED COMPD RAD, V49, P1141, DOI 10.1002/jlcr.1116 | - |
dc.description.citedreference | Patterson D, 2006, BRIT J CLIN PHARMACO, V62, P280, DOI 10.1111/j.1365-2125.2006.02658.x | - |
dc.description.citedreference | van Ahlen H, 2005, J SEX MED, V2, P856, DOI 10.1111/j.1743-6109.2005.00150.x | - |
dc.description.citedreference | Kloner RA, 2005, INT J IMPOT RES, V17, P450, DOI 10.1038/sj.ijir.3901360 | - |
dc.description.citedreference | Seftel AD, 2004, J UROLOGY, V171, P2341, DOI 10.1097/01.ju.0000125198.32936.38 | - |
dc.description.citedreference | Kloner RA, 2003, AM J CARDIOL, V92, p47M, DOI 10.1016/S0002-9149(03)00075-4 | - |
dc.description.citedreference | DUSING R, 2003, BLOOD PRESSURE, V2, P29 | - |
dc.description.citedreference | Vardi Y, 2002, UROLOGY, V59, P747 | - |
dc.description.citedreference | WALCZAK MK, 2002, J GEND SPECIF MED, V5, P19 | - |
dc.description.citedreference | ROHDE G, 2002, PHARMACOTHERAPY, V22, P418 | - |
dc.description.citedreference | PORST H, 2002, EUR UROL, V152, P599 | - |
dc.description.citedreference | Acevedo CG, 2001, LIFE SCI, V68, P2893 | - |
dc.description.citedreference | Fogari R, 2001, AM J HYPERTENS, V14, P27 | - |
dc.description.citedreference | Kloner RA, 2001, AM J HYPERTENS, V14, P70 | - |
dc.description.citedreference | Zusman RM, 2000, J HYPERTENS, V18, P1865 | - |
dc.description.citedreference | Burchardt M, 2000, J UROLOGY, V164, P1188 | - |
dc.description.citedreference | Chew KK, 2000, INT J IMPOT RES, V12, P41 | - |
dc.description.citedreference | Mikhailidis DP, 2000, CURR MED RES OPIN, V16, pS31 | - |
dc.description.citedreference | Srilatha B, 1999, INT J IMPOT RES, V11, P107 | - |
dc.description.citedreference | Webb DJ, 1999, AM J CARDIOL, V83, p21C | - |
dc.description.citedreference | Cannon RO, 1998, CLIN CHEM, V44, P1809 | - |
dc.description.citedreference | Panza JA, 1997, CLIN CARDIOL, V20, P26 | - |
dc.description.citedreference | FuglMeyer AR, 1997, INT J IMPOT RES, V9, P141 | - |
dc.description.citedreference | Rosen RC, 1997, UROLOGY, V49, P822 | - |
dc.description.citedreference | ANDERSSON KE, 1995, PHYSIOL REV, V75, P191 | - |
dc.description.citedreference | FELDMAN HA, 1994, J UROLOGY, V151, P54 | - |
dc.description.citedreference | DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.